Skip to main content
Complete Olympic Games coverage at your fingertips
Your inside track on the Olympic Games
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Complete Olympic Games coverage at your fingertips
Your inside track onthe Olympics Games
$1.99
per week
for 24 weeks
// //

South Africa is relying upon the Pfizer vaccine in its mass inoculation drive.

Denis Farrell/The Associated Press

A South African firm will begin producing the Pfizer-BioNTech COVID-19 vaccine, the first time that the shot will be produced in Africa, Pfizer announced Wednesday.

The Biovac Institute based in Cape Town will manufacture the vaccine for distribution across Africa, a move that should help address the continent’s desperate need for more vaccine doses amid a recent surge of cases.

Biovac will receive large batch ingredients for the vaccine from Europe and will blend the components, put them in vials and package them for distribution. The production will begin in 2022 with a goal of reaching more than 100 million finished doses annually. Biovac’s production of doses will be distributed among the 54 countries of Africa.

Story continues below advertisement

The development is “a critical step” in increasing African’s access to an effective COVID-19 vaccine, Biovac chief executive Dr. Morena Makhoana said.

Pfizer’s goal is to provide access to its vaccine to people everywhere, CEO Albert Bourla said. But the vast majority of its vaccine doses have been sold in bilateral deals to rich countries and only a small amount was made available to the U.N.-backed effort to share COVID-19 vaccines fairly.

For its mass inoculation drive, South Africa is relying on the Pfizer vaccine and has purchased 40 million doses, which are arriving in weekly deliveries.

The Johnson & Johnson vaccine is already being produced in South Africa. Aspen Pharmacare’s factory in Gqeberha, formerly Port Elizabeth, is making the J&J vaccine in the same “fill and finish” process and has the capacity to make more than 200 million doses of the vaccine annually. The J&J vaccines made in South Africa are also being distributed across the African continent.

South Africa’s vaccination drive is ramping up, with more than 220,000 people getting shots on weekdays. More than 5.5 million of South Africa’s 60 million people have received at least one jab, with more than 1.4 million fully vaccinated, according to official figures Wednesday.

South Africa’s goal is to vaccinate about 67% of its population by February 2022.

Vaccination levels are low across Africa, with less than 2% of the continent’s population of 1.3 billion having received at least one shot, according to the Africa Centers for Disease Control and Prevention.

Story continues below advertisement

To help alleviate the vaccine shortage on the continent, the U.S. is delivering in the coming weeks the first batches of 25 million doses of vaccines it is sharing with the African Union.

Senegal, Burkina Faso and Gambia have received about 151,200 doses of the Janssen jab as part of a first delivery that will be increased in coming weeks. Ethiopia and Djibouti are also receiving doses.

Gayle Smith, the U.S. Global COVID-19 Response Coordinator, said the U.S. is working with African partners to move the vaccines out as quickly as possible.

“We are doing this with no strings attached,” she said. “We want to see Africa defeat this pandemic. We want to see Africa be resilient and thrive.”

Currently, Africa is 99% dependent on imports for its vaccines, she said. The U.S. is investing in both South Africa and Senegal to help increase the speed and ability of Africa to produce its own vaccines, she said.

Senegal, the European Union and the U.S. recently signed an investment agreement to build a new vaccine manufacturing plant in Dakar, which will lead to the production of COVID-19 vaccines in Senegal.

Story continues below advertisement

Many African countries depending on vaccines from the U.N.-backed effort known as COVAX, have been left waiting for months. The effort has delivered only 200 million vaccines globally since February, while the U.S. alone has administered more than 338 million doses. After COVAX’s biggest supplier – the Serum Institute of India – halted exports in March to deal with an explosive surge on the subcontinent, the agencies behind COVAX, including the World Health Organization, resorted to begging rich countries for donations.

Most of the promised doses won’t arrive until next year and although Group of Seven countries pledged to donate a billion COVID-19 vaccines, that is far short of the 11 billion WHO says are needed to protect the world.

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies